Erika P. Hamilton, MD

Articles

Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast Cancer

August 22nd 2024

Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm

August 7th 2024

Erika P. Hamilton, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-low breast cancer.

Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 16th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer

July 16th 2024

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.

Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 9th 2024

Key opinion leaders discuss other clinical trials, including the EMERALD study, and targeted therapies for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in later lines of therapy.

Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291

July 9th 2024

Erika P. Hamilton, MD, discusses the CAPItello-291 trial, which investigated the combination of capivasertib and fulvestrant in advanced HR+, HER2- locally advanced or metastatic breast cancer and led to its FDA approval, emphasizing the improved progression-free survival observed in patients with PIK3CA, AKT1, and PTEN alterations.

Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 3rd 2024

The panel examines how resistance mutations influence the efficacy of subsequent treatment lines and delves into the process of selecting later-line therapies based on next-generation sequencing results.

Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway

July 2nd 2024

Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- locally advanced or metastatic breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.

Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

June 26th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance

June 26th 2024

Medical experts share their strategies for choosing initial treatment options for HR+/HER2- locally advanced or metastatic breast cancer, debating the most effective frontline therapies based on clinical trial evidence, while also discussing their aspirations for a new standard of care, and the challenges of managing disease progression.

HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

February 5th 2024

Erika Hamilton, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Dr Hamilton on the Benefit Derived From Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 8th 2023

Erika P. Hamilton, MD, discusses the benefit seen with adjuvant ribociclib in patients with hormone receptor-positive,HER2-negative breast cancer.

Dr Hamilton on the Use of ADCs in Breast Cancer

August 23rd 2023

Erika P. Hamilton, MD, discusses the use and sequencing of antibody-drug conjugates in patients with hormone receptor-positive/HER2-negative and HER2-low breast cancer.

Dr Hamilton on the Investigation of HER3-DXd in ER+ Breast Cancer and TNBC

June 23rd 2023

Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.

Dr Hamilton on the Efficacy and Safety of Abemaciclib Plus ET in Elderly Patients With HR+/HER2- Breast Cancer

June 8th 2023

Erika P. Hamilton, MD, discusses the efficacy and safety of adjuvant abemaciclib plus endocrine therapy in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer according to age.

Dr Hamilton on the Potential of RLY-2608 in PI3K-Mutated Breast Cancer

April 21st 2023

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.

Dr. Hamilton on Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 28th 2022

Erika P. Hamilton, MD, discusses previously reported and anticipated findings from the DESTINY-Breast03 trial, which compared the efficacy of 2 antibody-drug conjugates, fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer.

Dr. Hamilton on Tests to Identify HER2-Low and HER2+ Breast Cancer

August 10th 2022

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Dr. Hamilton on the EMERALD Trial in ER-Positive/HER2-Negative Breast Cancer

June 14th 2022

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Hamilton on the Utility of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

October 12th 2021

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.